echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > PerkinElmer will acquire antibody manufacturer BioLegend for US$5.25 billion

    PerkinElmer will acquire antibody manufacturer BioLegend for US$5.25 billion

    • Last Update: 2021-07-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    PerkinElmer said on Monday that it has agreed to acquire BioLegend, a manufacturer of life science antibodies and reagents, for approximately $5.


    This acquisition is the largest acquisition in PerkinElmer's history and is expected to be completed by the end of 2021


    BioLegend currently has more than 700 employees, most of them in the United States.


    Prahlad Singh, President and CEO of PerkinElmer, said: “We believe that (BioLegend) joining our team provides a rare opportunity to help life science researchers use evolving technologies and novel methods to better understand and fight against Disease


    He added on the conference call that the merger of the two companies has created a "true powerhouse who will be able to accelerate scientific progress and new product innovation throughout the company and around the world


    PerkinElmer expects that this transaction will boost its existing revenue growth and provide $0.


    In addition, PerkinElmer also reported that its second-quarter revenue increased by 51% year-on-year


    Jamie Mock, PerkinElmer's chief financial officer, said that organic revenue growth has reached 41%


    According to Mock, in the second quarter of 2021, COVID-19-related products and services contributed $365 million in revenue because the market's demand for PCR testing and RNA extraction products did not decrease as the company expected


    The immunodiagnostics business of the diagnostics department remained strong this quarter, with a year-on-year growth of more than 100%


    PerkinElmer said that the profit in the second quarter was $245.


    The company's R&D expenditures increased to US$65.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.